Search Results1-9 of  9

  • SHIBAYAMA Hirohiko ID: 9000000184666

    Department of Hematology and Oncology, Osaka University Graduate School of Medicine (2017 from CiNii)

    Articles in CiNii:10

    • 白血病細胞におけるユビキチンの定量的解析 (1996)
    • New non-invasive evaluation of anticancer drugs. Plasma diamine oxidase activity. (1988)
    • Supportive care in multiple myeloma for continuing anti-myeloma therapies (2014)
  • SHIBAYAMA Hirohiko ID: 9000000568455

    Department of Hematology and Oncology, Osaka University Graduate School of Medicine (2009 from CiNii)

    Articles in CiNii:4

    • Early age onset of hairy cell leukemia presenting with leukocytosis (1996)
    • Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma : comparison with serum soluble interleukin-2 receptor values (2009)
    • Constitutive Activation of c-kit by the Juxtamembrane but Not the Catalytic Domain Mutations Is Inhibited Selectively by Tyrosine Kinase Inhibitors STI571 and AG1296 (2002)
  • SHIBAYAMA Hirohiko ID: 9000002132352

    Articles in CiNii:13

    • Anamorsin, a cell-death-defying factor, and lymphoid neoplasm (2008)
    • 造血細胞の発生と抗アポトーシス分子Anamorsin (2004)
    • Tumor markers in hematological malignancies (2012)
  • SHIBAYAMA Hirohiko ID: 9000018775000

    Department of Hematology and Oncology, Osaka University Hospital (2011 from CiNii)

    Articles in CiNii:1

    • Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase : results from the Japanese subgroup of ENESTnd (2011)
  • SHIBAYAMA Hirohiko ID: 9000258036568

    Division of Internal Medicine, Department of Clinical Research, Research Institute for Microbial Diseases, Osaka University (1993 from CiNii)

    Articles in CiNii:1

    • Multiple Myeloma and Adhesion Molecules (1993)
  • Shibayama Hirohiko ID: 9000347362547

    Articles in CiNii:1

    • Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma (2016)
  • Shibayama Hirohiko ID: 9000389945512

    Articles in CiNii:1

    • Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment (2018)
  • Shibayama Hirohiko ID: 9000403298679

    Department of Hematology and Oncology, Osaka University Graduate School of Medicine (2019 from CiNii)

    Articles in CiNii:1

    • OSAKA METHOD (0.01 mol/<i>l</i> DTT) EFFECTIVELY NEGATES DARATUMUMAB INTERFERENCE: A PATIENT WITH MULTIPLE MYELOMA AND DIFFICULT-TO-OBTAIN PREVIOUS MEDICAL HISTORY (2019)
  • Shibayama Hirohiko ID: 9000404344083

    Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan (2020 from CiNii)

    Articles in CiNii:1

    • Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis (2020)
Page Top